{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"populationDescription":"All Treated Population. Participants with incomplete response dates were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Duration of Response-Part 1 BID","type":"SECONDARY"}